Sciwind Biosciences Announces Positive Interim Results from Ongoing Phase 2b Clinical Trial of XW003 (Ecnoglutide) in Patients with Obesity
/PRNewswire/ -- Sciwind Biosciences, a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic...
Source: prnewswire.com